James Ignatz-Hoover, MD, PhD
-
Specialty: Hematology and Oncology
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: English
Office Locations
UH Seidman Cancer Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-3951
Biography: James Ignatz-Hoover, MD, PhD
Expertise
Certifications & Memberships
- Hematology - American Board of Internal Medicine
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Fellowship | Hematology/Oncology
Hematology/Oncology - UH Cleveland Medical Center (2020 - 2023)
Residency | Internal Medicine
Internal Medicine - UH Cleveland Medical Center (2018 - 2021)
Medical Education
Case Western Reserve University School Of Medicine (2018)
Other Education
Case Western Reserve University (2017)
Undergraduate
University Of Michigan (2010)
About
James Ignatz-Hoover, MD, PhD, is a hematologist/oncologist at UH Seidman Cancer Center specializing in blood cancers such as multiple myeloma and AL amyloidosis. Dr. Ignatz-Hoover is board certified in hematology, medical oncology and internal medicine.
As an undergraduate, Dr. Ignatz-Hoover attended University of Michigan, earning a Bachelor of Science in biochemistry in 2010. He then joined the medical scientist training program at Case Western Reserve School of Medicine (Cleveland, Ohio), where he obtained a PhD in Pathology in 2017 and MD in 2018. His post-graduate medical training at UH Cleveland Medical Center included an internal medicine residency completed in June of 2020 and hematology/oncology fellowship completed in June 2024.
Dr. Ignatz-Hoover is a winner of the American Society of Clinical Oncology Young Investigator Award and received individual NIH funding supporting his doctoral training.
As a guest speaker, Dr. Ignatz-Hoover has lectured and presented locally and nationally, including at meetings of the Society of Hematology and Oncology, American Society of Hematology and American Association of Cancer Research, covering such topics as new therapies for managing acute myeloid leukemia and multiple myeloma. He has been invited to give expert commentary at OncLive State of the Science Summit.
Dr. Ignatz-Hoover has contributed original articles to various peer-reviewed journals, including Cancer Research Communications, Molecular Cancer Therapeutics, Nature Communications, Blood Advances, Leukemia, Frontiers in Cellular and Infection Microbiology, Oncology, Frontiers in Oncology, Cancer Research, Journal of Immunology, and Clinical and Vaccine Immunology. He serves as an expert reviewer for the journal Leukemia and Lymphoma.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, James Ignatz-Hoover did not disclose any Outside Relationships with Industry.